Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the AndroCoV clinical scoring system may be a more sensitive and cost-effective tool for diagnosing COVID-19 compared to RT-PCR-SARS-CoV-2 tests, potentially reducing diagnostic delays and false negatives.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

In this study, nandrolone decanoate treatment in rats caused persistent diestrus and altered steroid receptor expression and sex hormones, especially at higher doses, with partial reversibility at lower doses over time.

This study observed that early treatment with azithromycin and either nitazoxanide, ivermectin, or hydroxychloroquine in COVID-19 patients may reduce viral shedding, symptom duration, and respiratory complications compared to untreated patients.

This study found that the Elastic Verhoeff–Van Gieson stain may help differentiate between follicular streamers and scars in cicatricial and noncicatricial alopecias by highlighting differences in the elastic fiber network on horizontal scalp biopsy sections.

Hair loss may link to weaker COVID-19 immunity, suggesting possible need for extra vaccine boost.

This study found that eccrine duct dilation is significantly more frequent in cicatricial alopecias compared to noncicatricial alopecias, possibly due to the scarring process.

This case report highlights a rare instance of CD8-positive hypopigmented mycosis fungoides causing alopecia areata-like changes, emphasizing the necessity of scalp biopsy in such presentations.

This article discusses the role of Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants in predicting the response to oral minoxidil for treating female pattern hair loss, without presenting new research findings.

This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.

This study found that early pharmacological treatment of COVID-19 in females, including those with hyperandrogenic conditions, significantly improved clinical outcomes, with spironolactone users experiencing milder symptoms and faster recovery.

This letter discusses how severe baldness in men is associated with higher risk of severe COVID-19, and highlights research suggesting antiandrogen medications may improve outcomes.

This study found that the presence of premature desquamation of the inner root sheath in noninflamed hair follicles is a relatively specific marker for diagnosing central centrifugal cicatricial alopecia.

This study suggests that certain climate factors, particularly UV index and precipitation, may influence seasonal flare patterns in children with alopecia areata, especially those with atopic conditions.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This review discusses the impact of dermatologic conditions and treatments on blood donation eligibility in Brazil and provides guidance for dermatologists but reports no new findings.

In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.

This study reported that more sensitive, early diagnosis and treatment of COVID-19 with drug combinations significantly improved clinical outcomes in males with or without androgenetic alopecia, preventing severe progression.

This study found that naked hair shafts significantly increased in cicatricial alopecias compared to non-cicatricial types, suggesting their potential use in diagnosing cicatricial alopecia.

This observational study reports that a TRASER device using specific wavelengths for vascular and follicular targets showed both clinical responses and histological changes, suggesting its potential as an effective vascular and hair removal tool.

This paper introduces a novel topical booster aimed at enhancing follicular sulfotransferase activity to potentially improve minoxidil response in patients with androgenetic alopecia but reports no new clinical results.

This study found that multiple eccrine duct dilation is highly specific for diagnosing cicatricial alopecia and may indicate scarring processes, aiding in accurate differential diagnosis from noncicatricial alopecias.

This letter discusses existing research and encourages further studies on the relationship between androgenetic alopecia and COVID-19 severity, reporting no new clinical results.

This study suggests that BTP levels in cerebrospinal fluid might help diagnose CIDP and predict therapy response but require validation in larger cohorts.

Most men prefer keeping their eyebrows over scalp hair.

This study found that 63.4% of androgenetic alopecia patients showed clinical improvement after 6 months of low-dose oral minoxidil, with patients having low sulfotransferase activity in hair follicles responding more favorably than those with high enzyme activity.